Stock AVDL AVADEL PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Avadel Pharmaceuticals plc

Equities

AVDL

US05337M1045

Real-time Estimate Cboe BZX
Other stock markets
 02:41:23 2024-04-16 pm EDT 		5-day change 1st Jan Change
17.69 USD +4.06% Intraday chart for Avadel Pharmaceuticals plc +5.58% +25.39%
Apr. 15 European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
Apr. 11 European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AVADEL PHARMACEUTICALS PLC Stock Avadel Pharmaceuticals plc
+20.40% 1.45B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.79% 677B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.94% 560B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.84% 355B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.75% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.32% 287B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+4.00% 214B
B+
NOVARTIS AG Stock Novartis AG
+1.92% 207B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 199B
A+
PFIZER, INC. Stock Pfizer, Inc.
-10.00% 146B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AVDL Stock
  4. Ratings Avadel Pharmaceuticals plc